Home / Recalls / TAILSTORM HEALTH INC / D-0594-2024

D-0594-2024 Class II Ongoing

Recalled by TAILSTORM HEALTH INC — Chandler, AZ

Recall Details

Product Type
Drugs
Report Date
July 17, 2024
Initiation Date
July 3, 2024
Termination Date
N/A
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
12,525 10 mL vials

Product Description

Lidocaine HCL Injection, USP 2% 200mg/10mL (20mg/mL) and EPINEPHRINE HCl 1:200,000, 10 ml Single Dose Vial, Rx only, Compounded drug by Medivant Healthcare, 158 S Kyrene Rd, Chandler, AZ 85226, NDC 81483-0038-0, UPC 3 81483 00380 2

Reason for Recall

Subpotent Drug: reduced efficacy for epinephrine

Distribution Pattern

Nationwide in the USA

Code Information

Lot Number: 2311003, Expiration Date: 11/13/2024

Other recalls by TAILSTORM HEALTH INC

  • D-0503-2025 Class II — LIDOcaine HCL Sterile Injection, USP, 20 mg/mL, 2%, (200 mg/10 mL), For Infiltra (June 2, 2025)
  • D-0499-2025 Class II — BUPIVAcaine HCL Sterile injection, USP w/EPINEPHRINE 1:200,000, 50 mg/10mL, 0.5% (June 2, 2025)
  • D-0501-2025 Class II — KETAmine Hydrochloride Injection, USP, 500mg/5mL, (10mg/mL), For IM or Slow IV U (June 2, 2025)
  • D-0502-2025 Class II — LIDOcaine HCL Sterile Injection, USP, 100mg/10mL, 1%, (10mg/mL), w/EPINEPHRINE 1 (June 2, 2025)
  • D-0500-2025 Class II — KETAmine Hydrochloride Injection, USP, 50 mg/5mL (10 mg/mL), For IM Use or Slow (June 2, 2025)
  • D-0498-2025 Class II — LIDOcaine HCl Injection, USP, 10mg/mL, 1% (100 mg/10mL), 10 mL Sterile Single Do (June 2, 2025)
  • D-0051-2025 Class II — BEVACIZUMAB (AVASTIN)1.25mg/0.05mL, Sterile Injection, 0.5 mL Single-Dose Syring (November 6, 2024)